VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
AGL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
AGLAgilon Health, Inc.
$115.20$1.9B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksAGLCash Flow

Agilon Health, Inc. (AGL) Cash Flow Statement

7Y historyFree accessUpdated daily

Free cash flow was negative in most recent quarters and turned positive only to $46.6M (a 3.1% margin) in the latest quarter, while operating cash flow to net income ratios ranged from -3.19 to 1.43, indicating erratic conversion that investors should monitor.

Income StatementBalance SheetCash FlowRatios

AGL Cash Flow Statement

Annual statement

AGL Cash Flow Statement

Agilon Health, Inc. (AGL) cash flow statement — 7-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19
Cash from Operations-4.23M-105.76M-57.78M-156.2M-130.81M-148.16M-53.2M-103.86M
Operating CF Margin %--1.78%-0.95%-3.62%-5.48%-9.74%-4.37%-13.07%
Operating CF Growth %260.51%-83.05%63.01%-19.41%11.71%-178.47%48.77%-
Net Income-106.04M-391.35M-260.1M-262.8M-106.86M-406.79M-60.05M-282.74M
Depreciation & Amortization27.36M28.59M24.46M20.16M13.77M14.67M14.1M41.41M
Stock-Based Compensation58.47M49.12M50.66M69.33M28.38M292.39M6.69M5.22M
Deferred Taxes0000532K-3.23M-2.81M-16.18M
Other Non-Cash Items48.77M18.4M-3.38M27.18M-7.19M9.82M-17.6M115.24M
Working Capital Changes-51.73M189.47M130.59M-10.07M-59.44M-55.02M6.47M33.18M
Change in Receivables0344.58M-74.58M0-204.17M-149.04M-59.38M-23.28M
Change in Inventory00000149.04M00
Change in Payables0-87.48M198.58M473.61M173.45M95.7M67.31M38.26M
Cash from Investing79.59M88.61M139.89M-44.02M-444.39M-90.51M22.07M-5.06M
Capital Expenditures-15.46M-13.24M-13.25M-15.83M-15.43M-13.43M-2.35M-3.91M
CapEx % of Revenue0.26%0.22%0.22%0.37%0.65%0.88%0.19%0.49%
Acquisitions000-43.06M500K-1.34M26.2M0
Investments--------
Other Investing-5.99M-31.87M-41.77M-34.51M-23.75M-75.74M-1.79M-1.15M
Cash from Financing-657K-2.99M-2.58M-193.13M28.06M1.15B24.62M176.3M
Debt Issued (Net)-3.5M0-3.75M-5M-5M-19.9M-3.04M-3.59M
Equity Issued (Net)4.46M-2.99M1.17M-200M33.06M1.19B27.66M180.19M
Dividends Paid00000000
Share Repurchases-17K-2.99M0-200M00-6.74M0
Other Financing-1.61M0011.87M0-14.74M0-303K
Net Change in Cash74.69M-20.15M79.53M-393.35M-547.14M915.73M-6.52M67.38M
Free Cash Flow-31.07M-119M-71.03M-187.01M-163.47M-161.59M-55.55M-107.77M
FCF Margin %-0.52%-2.01%-1.17%-4.33%-6.84%-10.62%-4.56%-13.57%
FCF Growth %68.46%-67.55%62.02%-14.4%-1.17%-190.86%48.45%-
FCF per Share-1.76-7.19-4.32-11.43-10.01-10.83-3.61-7.02
FCF Conversion (FCF/Net Income)0.29x0.26x0.22x0.59x1.23x0.36x0.89x0.37x
Interest Paid1.23M04.6M5.8M3.67M4.82M7.09M0
Taxes Paid650K01.8M5.36M5.31M1.82M2K0

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Operating cash flow volatility and medical cost pressure

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Operating Cash Conversion Remains Erratic

Based on AGL's reported quarterly figures, operating cash flow to net income ratios swung from -3.19 to 1.43 across recent quarters, a range too wide to establish a reliable earnings-to-cash conversion pattern for the business.

The conversion ratio is distorted by the presence of net losses in several quarters, which mechanically produces misleading ratios when the denominator is negative. The latest quarter's 1.43 ratio appears favorable, but it follows a quarter with operating cash outflow of $57.3M despite positive net income of $18.0M, which suggests working capital timing is driving much of the variance. Investors should monitor whether operating cash flow stays positive across multiple consecutive quarters before concluding that cash generation has structurally improved.

Free Cash Flow Turned Positive Only Recently

As reported in AGL's cash flow statements, free cash flow was negative in most of the ten quarters shown, with the latest quarter delivering $46.6M and a 3.1% margin that remains a single-quarter data point.

Across the window, free cash flow ran negative in roughly seven of ten quarters, with the deepest outflow of $60.7M occurring in the most recent full quarter before the latest print. The positive result in the latest period is heavily influenced by a $114.0M working capital reversal in the prior quarter and a $82.7M working capital inflow in 2025Q4, implying the cash result is partly timing-driven rather than purely operational. Until positive FCF persists without large working capital swings, the trajectory should be treated as unproven.

Working Capital Swings Dominate Cash Results

Based on AGL's reported figures, working capital changes ranged from a -$114.0M outflow to a +$105.8M inflow across recent quarters, magnitudes that exceed the company's reported net income in several periods and dominate the cash outcome.

Such large and alternating working capital movements are consistent with the timing of medical claims payables and IBNR-related accruals rather than steady collection or payment patterns. When working capital flows are this volatile relative to earnings, reported cash flow becomes a weak indicator of underlying operating performance. Investors should track whether these swings reverse over time, since persistent one-directional movements would raise questions about the accuracy of accrual estimates.

Asset-Light Model Limits Capital Needs

According to reported cash flow data, AGL's capital expenditures remained between roughly 0.2% and 1.2% of revenue, indicating a very light capital base that keeps investment needs modest relative to the business scale.

Capex has been consistently small, with the exception of a $14.4M inflow in 2024Q3 that likely reflects a disposal or reclassification rather than negative investment. Depreciation and amortization of roughly $6M to $7M per quarter exceeds capex in most periods, suggesting the company is not currently reinvesting heavily in its physical or technology base. This favors free cash flow conversion over time, though low investment may also reflect limited build-out of the platform relative to its growth ambitions.

Stock Compensation Inflates Cash Picture

Based on AGL's reported figures, stock-based compensation of $6.3M to $23.8M per quarter is added back in operating cash flow, meaning a portion of reported cash generation reflects non-cash equity expense rather than economic cash earnings.

Because SBC is a non-cash charge, it lifts operating cash flow relative to net income, and in periods where net income was negative this adjustment may partly offset losses in the cash presentation. Investors should consider whether the cash-based view flatters performance, particularly given the company's continued losses at the operating level. Evaluating free cash flow net of SBC would provide a more conservative picture of cash generation.

AGL — Frequently Asked Questions

Quick answers to the most common questions about buying AGL stock.

How much cash does Agilon Health, Inc. (AGL) generate from operations?

Agilon Health, Inc. (AGL) generated $-105.8M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Agilon Health, Inc.'s free cash flow?

Agilon Health, Inc. (AGL) reported negative free cash flow of $119.0M in 2025, indicating capital requirements exceeded cash from operations.

What is Agilon Health, Inc.'s capital expenditure (CapEx)?

Agilon Health, Inc. (AGL) spent $13.2M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does Agilon Health, Inc. distribute cash to shareholders?

In 2025, Agilon Health, Inc. (AGL) spent $3.0M on share repurchases. This shows the company's commitment to returning capital to its equity investors.